Barclays Issues Pessimistic Forecast for Cellectis (NASDAQ:CLLS) Stock Price

Cellectis (NASDAQ:CLLS) had its price objective lowered by research analysts at Barclays from $7.00 to $5.00 in a report issued on Tuesday, Benzinga reports. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. Barclays‘s price target suggests a potential upside of 185.71% from the company’s previous close.

Separately, StockNews.com started coverage on shares of Cellectis in a report on Tuesday. They set a “sell” rating for the company.

Cellectis Price Performance

Shares of NASDAQ:CLLS opened at $1.75 on Tuesday. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.92 and a quick ratio of 1.92. Cellectis has a 12 month low of $1.75 and a 12 month high of $3.77. The firm has a market capitalization of $97.27 million, a P/E ratio of -1.35 and a beta of 3.10. The company’s fifty day moving average price is $2.07 and its 200 day moving average price is $2.27.

Cellectis (NASDAQ:CLLS) last announced its earnings results on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). The firm had revenue of $18.05 million during the quarter, compared to analyst estimates of $5.00 million. Cellectis had a negative net margin of 401.83% and a negative return on equity of 78.90%. During the same period last year, the company earned ($0.31) earnings per share. As a group, sell-side analysts predict that Cellectis will post -0.54 earnings per share for the current fiscal year.

Institutional Trading of Cellectis

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Long Focus Capital Management LLC raised its stake in Cellectis by 2.9% in the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock valued at $8,634,000 after purchasing an additional 130,000 shares during the last quarter. Principal Financial Group Inc. grew its holdings in Cellectis by 2.9% in the second quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock valued at $817,000 after purchasing an additional 12,467 shares during the period. First Affirmative Financial Network acquired a new position in shares of Cellectis in the 3rd quarter valued at $45,000. Finally, XTX Topco Ltd purchased a new position in shares of Cellectis in the 2nd quarter worth $29,000. 63.90% of the stock is currently owned by hedge funds and other institutional investors.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.